Carasent’s Q3 report was stable and better than what it appears at face level. Some onboarding delays mask Evimeria’s underlying organic growth, which we believe will be resolved over the next couple of quarters. Still, organic growth was 26% in the quarter (29% excluding the new acquisition of Metodika).